Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Saved in:
| Title: | Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial. |
|---|---|
| Authors: | Rose AAN; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada. april.rose@mcgill.ca.; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada. april.rose@mcgill.ca.; Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada. april.rose@mcgill.ca.; Division of Experimental Medicine, McGill University, Montreal, QC, Canada. april.rose@mcgill.ca.; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. april.rose@mcgill.ca., Maxwell J; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.; Division of Experimental Medicine, McGill University, Montreal, QC, Canada., Rousselle E; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.; Division of Experimental Medicine, McGill University, Montreal, QC, Canada., Mukonoweshuro CL; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.; Division of Experimental Medicine, McGill University, Montreal, QC, Canada., Elkholi IE; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada.; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada., Riaud M; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada.; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada., Biondini M; Goodman Cancer Institute, McGill University, Montreal, QC, Canada., Cianfarano E; Montreal Neurological Institute, McGill University, Montreal, QC, Canada., Soria-Bretones I; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada.; Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Tobin C; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., McGuire M; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Law RWY; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Elia AJ; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Wang BX; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., King I; Division of Clinical Laboratory Genetics, University Health Network, Toronto, ON, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada., Zhang T; Division of Clinical Laboratory Genetics, University Health Network, Toronto, ON, Canada., Pugh TJ; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.; Ontario Institute for Cancer Research, Toronto, ON, Canada., Kamil ZS; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada., Butler M; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Division of Medical Oncology, University of Toronto, Toronto, ON, Canada., Shepherd FA; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Division of Medical Oncology, University of Toronto, Toronto, ON, Canada., Leighl NB; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Division of Medical Oncology, University of Toronto, Toronto, ON, Canada., Razak AA; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Division of Medical Oncology, University of Toronto, Toronto, ON, Canada., Hansen A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Division of Medical Oncology, University of Toronto, Toronto, ON, Canada., Saibil SD; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Division of Medical Oncology, University of Toronto, Toronto, ON, Canada., Bedard PL; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Division of Medical Oncology, University of Toronto, Toronto, ON, Canada., Siegel PM; Division of Experimental Medicine, McGill University, Montreal, QC, Canada.; Goodman Cancer Institute, McGill University, Montreal, QC, Canada., Siu LL; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Division of Medical Oncology, University of Toronto, Toronto, ON, Canada., Cescon DW; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.; Division of Medical Oncology, University of Toronto, Toronto, ON, Canada., Spreafico A; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. anna.spreafico@uhn.ca.; Division of Medical Oncology, University of Toronto, Toronto, ON, Canada. anna.spreafico@uhn.ca. |
| Source: | Nature communications [Nat Commun] 2026 Jan 03; Vol. 17 (1), pp. 1323. Date of Electronic Publication: 2026 Jan 03. |
| Publication Type: | Journal Article; Clinical Trial, Phase II |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-025-68076-7 |
